Intellectual property

Topelia leads the world in IP lodgement for its unique combination therapy, ZIVERDOX and has multi-faceted IP protection. Topelia has filed three patent families covering ZIVERDOX plus a range of adjacent permutations, with the reassurance that combination therapies are harder to “innovate around” than single molecules. The priority filing dates between March to May 2020 with ongoing expanding additions to the ‘families’ mean that the 20-year patent protection provides ample time to scale the distribution and use of ZIVERDOX products globally. All patents are composition and use patents passing through the examination process

Topelia also has an active strategy for expanding its patent base in the long term to further strengthen its intellectual property rights. In addition to the legal protection that Topelia holds due to its patent portfolio, Topelia and its consultants possess a large number of business secrets and a strong know-how that is difficult for competitors to reproduce.